Table 1. Distribution of cells in cell cycle with PRL-3 overexpression and inhibition.
| A | ||||||
|---|---|---|---|---|---|---|
| INA-6-MOCK No IL-6 | INA-6-PRL-3 No IL-6 | INA-6-MOCK 0,01 ng/mL IL-6 | INA-6-PRL-3 0,01 ng/mL IL-6 | INA-6-MOCK 1 ng/mL IL-6 | INA-6-PRL-3 1 ng/ml IL-6 | |
| G1 (%) | 27 | 22* | 25 | 21 | 21 | 21 |
| S (%) | 59 | 54* | 59 | 55* | 59 | 55 |
| G2M (%) | 14 | 24* | 16 | 23* | 20 | 24* |
| B | ||||
|---|---|---|---|---|
| INA-6 Control | INA-6 10 μM PRL-3 inh | INA-6 20 μM PRL-3 inh | INA-6 40 μM PRL-3 inh | |
| G1 (%) | 21 | 22 | 25 | 24 |
| S (%) | 57 | 57 | 60 | 58 |
| G2M (%) | 22 | 21 | 16 | 18 |
Cell cycle analysis using PI uptake and flow cytometry. Percentage of cells in G1, S and G2M phases of cell cycle. (A) INA-6-MOCK and INA-6-PRL-3 cultivated for 24 hours in the absence of IL-6 or with 0,01 ng/mL or 1 ng/ml IL-6. (B) INA-6 wild type cultivated for 24 hours in the presence of 1 ng/mL IL-6 and different concentrations of PRL-3 inhibitor I.
*
denotes statistically significant difference from control group, p < 0.05.